BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW)

CUSIP: 10778Y112

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / *W EXP 02/26/202
Total 13F shares
1,546,452
Share change
+40,242
Total reported value
$3,292,139
Price per share
$2.06
Number of holders
8
Value change
+$77,916
Number of buys
2
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP 10778Y112?
CUSIP 10778Y112 identifies BCTXW - BriaCell Therapeutics Corp. - *W EXP 02/26/202 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW) as of Q4 2022

As of 31 Dec 2022, BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW) was held by 8 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,546,452 shares. The largest 8 holders included Murchinson Ltd., ARMISTICE CAPITAL, LLC, Privium Fund Management B.V., K.J. Harrison & Partners Inc, Redmond Asset Management, LLC, ZEKE CAPITAL ADVISORS, LLC, UBS Group AG, and BANK OF AMERICA CORP /DE/. This page lists 8 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.